Vigil Neuroscience (VIGL) shares surged over 26% in recent Thursday trading following positive results from a Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease, supporting its advancement to a mid-stage clinical trial.
The initial Phase 1 study demonstrated a favorable safety and tolerability profile for VG-3927 across all subjects, including elderly participants.
VG-3927 achieved a dose-dependent reduction of soluble TREM2 levels in cerebrospinal fluid by about 50% and showed activation of the TREM2 receptor, which is believed to support brain health through microglial activity.
Based on these findings, Vigil said it plans to advance a once-daily oral dose of 25 milligrams into a Phase 2 trial, expected to begin in Q3.
Price: 2.56, Change: +0.53, Percent Change: +26.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。